Pfizer Says Representatives Are Critical Competitive Advantage and Core
Asset in Communicating Value of Medicines
NEW YORK, Nov. 28 /PRNewswire-FirstCall/ -- As part of its strategy to
most effectively and efficiently meet customer needs as well as match the
organization's business needs, Pfizer said today that it will realign its
U.S. sales organization.
The company will reduce the U.S. sales organization by approximately 20
percent, while maintaining strong support for all of its in-line products,
including Lipitor, Celebrex and Geodon, as well as important new products
such as Lyrica, Exubera, Chantix and Sutent.
Pfizer announced in mid-October that it would undertake a comprehensive
review of every aspect of its company-wide operations with the goals of
being more agile, effective and capable of best ensuring success today and
in the future. In January, Pfizer will present its long-term outlook and
its additional actions for transforming the company.
"The changes we are making today will better align our sales
organization to our overall customer and business needs. This is an
important step toward making Pfizer a more agile and effective company,"
said Jeffrey B. Kindler, Pfizer's chief executive officer. "Our field force
will now be in a much better position to adapt to changes in our product
mix and capitalize on the growth opportunities we see for our innovative
medicines. While we pursue these opportunities and respond to the
accelerating changes in our marketplace, our field force will continue to
be a critical competitive advantage in ensuring the success of both our
products and our company as a whole. The relationship of our
representatives with physicians and health care professionals is one of
Pfizer's most important assets. We are committed to giving our
representatives all the support and tools they need to make an even greater
contribution to our success going forward."
Ian Read, president of Pfizer Worldwide Pharmaceutical Operations,
said, "The U.S. sales organization has done an outstanding job this year.
At the same time, it is incumbent upon us to look ahead and carefully
assess our changing marketplace and all the factors affecting our outlook,
so that we can align our organization to properly support our key products
and customer needs.
"As we do this, I am confident we will maintain our sales leadership
and our representatives will continue their critical work in communicating
important medical information to prescribing physicians. Consistent with
Pfizer's long-standing values, we will provide affected employees with
support services and benefits during their transitions. We will continue to
support and reward our top performers," Read said.
SOURCE Pfizer
 back to top
Related links:
http://www.pfizer.com
Photo Notes:A free corporate logo to accompany this
story is availableimmediately via Wieck Photo Database to any
media with telephoto receiver orelectronic darkroom, PC or
Macintosh, that can accept overhead transmissions.To retrieve a
logo, please call 972-392-0888./ /Company News On-Call:
http://www.prnewswire.com/comp/688250.html
Pfizer's press releases are available through PR Newswire's
Company News On-Call service on PRN's Web site. Visit
http://www.prnewswire.com/comp/688250.html/
CONTACT:
Paul Fitzhenry, +1-212-733-4637, or Shreya
Prudlo, +1-212-733-4889, both of Pfizer
|
